A5004441174- Cervical Cancer and HPV Research
- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- Genital Health and Disease
- Global Cancer Incidence and Screening
- Cancer Treatment and Pharmacology
- Brain Metastases and Treatment
- Breast Lesions and Carcinomas
- Statistical Methods and Inference
- Lung Cancer Treatments and Mutations
- Endometrial and Cervical Cancer Treatments
- Lung Cancer Research Studies
- Privacy-Preserving Technologies in Data
- Glioma Diagnosis and Treatment
- Reproductive tract infections research
- Anomaly Detection Techniques and Applications
- Breast Implant and Reconstruction
- Biomedical Text Mining and Ontologies
- HER2/EGFR in Cancer Research
- Statistical Methods and Bayesian Inference
- Cancer Genomics and Diagnostics
- Esophageal Cancer Research and Treatment
- Adversarial Robustness in Machine Learning
- Multiple and Secondary Primary Cancers
- Molecular Biology Techniques and Applications
Provincial Health Services Authority
2024
University of British Columbia
2016-2024
Simon Fraser University
2019-2023
BC Cancer Agency
2016-2023
Sylvester Comprehensive Cancer Center
2021
The Royal Melbourne Hospital
2021
Spinal Cord Injury BC
2021
Princess Margaret Cancer Centre
2019
Anna Needs Neuroblastoma Answers
2018
Vancouver Biotech (Canada)
2018
<h3>Importance</h3> There is limited information about the relative effectiveness of cervical cancer screening with primary human papillomavirus (HPV) testing alone compared cytology in North American populations. <h3>Objective</h3> To evaluate histologically confirmed cumulative incident intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+) detected up to and including 48 months by HPV (intervention) liquid-based (control). <h3>Design, Setting, Participants</h3> Randomized clinical trial...
Complete Round 1 data (baseline and 12-month follow-up) for HPV FOCAL, a randomized trial establishing the efficacy of DNA testing with cytology triage as primary screen cervical cancer are presented. Women were to one three arms: Control arm - Baseline liquid-based (LBC) ASCUS results triaged testing; Intervention Safety arms LBC positives. Results presented 15,744 women allocated (intervention safety combined) 9,408 control arms. For all age cohorts, CIN3+ detection rate was higher in...
Human papillomavirus (HPV)-based cervical cancer screening requires triage of HPV positive women to identify those at risk intraepithelial neoplasia grade 2 (CIN2) or worse. We conducted a blinded case-control study within the FOCAL randomized trial aged 25-65 examine whether baseline methylation testing using S5 classifier provided performance similar an algorithm relying on cytology and genotyping. Groups were randomly selected from with known HPV/cytology results pathology outcomes. Group...
Cervical cancer screening programs are switching from Pap to high-risk HPV testing.To compare the Aptima Assay (AHPV) with Hybrid Capture® 2 High-Risk DNA Test® (HC2) for primary cervical screening.HPV FOCAL is a randomized trial comparing HC2 liquid-based cytology (LBC) women aged 25-65. AHPV and were compared at baseline screen (n=3473). Genotyping was by 16 18/45 Genotype Assay. We assessed genotyping reflex LBC colposcopy triage.AHPV/HC2 agreement 96.5% (kappa 0.76); positive 77.4%. The...
(Abstracted from JAMA 2018;320:43–52) There are only limited data in North American populations on the relative diagnostic effectiveness of cervical cancer screening with primary human papillomavirus (HPV) testing alone compared cytology.
Long-term safety of a single negative human papillomavirus (HPV) test for cervical cancer screening is unclear. The HPV FOr cerviCAL Cancer Trial (FOCAL) was randomized trial comparing testing with cytology. FOCAL-DECADE cohort tracked women who received one during FOCAL, and were negative, up to 10 years identify intraepithelial neoplasia grade 2 or worse (CIN2+) 3 (CIN3+) detected through provincial program.FOCAL participants test, had at least post-FOCAL cervix screen included (N =...
Abstract While cervix screening using cytology is recommended at 2‐ to 3‐year intervals, given the increased sensitivity of human papillomavirus (HPV)‐based detect precancer, HPV‐based every 4‐ 5‐years. As organized programs transition from with extended there some concern that cancers will be missed between screens. Participants in HPV FOr CervicAL Cancer (HPV FOCAL) trial received (Cytology Arm) 24‐month intervals or 48‐month intervals; both arms co‐testing (cytology and testing) exit. We...
Shifting from cytology to human papillomavirus (HPV)-based cervical cancer screening will initially increase colposcopy referrals. The anticipated impact on health systems has been raised as a concern for implementation. It is unclear if the higher rate of referrals sustained after initial HPV-based screens or reverts new lower baselines due earlier detection and treatment precancer. This study aimed investigate long-term rates participation in screening.
Background The trial assigning individualized options for treatment (Rx) (TAILORx) confirmed the predictive value of 21‐gene recurrence score (RS) assay in hormone receptor (HR)–positive, HER2‐negative, node‐negative breast cancer and established thresholds chemotherapy benefit younger older patients. Real‐world use RS‐guided costs British Columbia post‐TAILORx were examined. Methods authors assembled 3 cohorts HR‐positive, patients with defined by diagnosis: before RS funding (cohort 1...
The HPV FOCAL Trial is a RCT comparing human papilloma virus (HPV) with Liquid Based Cytology (LBC) screening for cervical cancer. Results are presented the comparison of Safety and Control arms after two rounds. included randomisation women aged 25–65 into arm, where they were initially screened received entry LBC, both again LBC at 24 months. There 6203 (Safety) 6075 (Control) in this analysis. For vs arms, Round 1 resulted increased detection intraepithelial neoplasia 2 or worse...
Objective To study participant’s acceptability of and attitudes towards human papillomavirus (HPV) testing compared with cytology for cervical cancer screening what impact having an HPV positive result may have in future screening. Design Cross-sectional online survey clinical trial participants. Setting Primary care, population-based Cervix Screening Program, British Columbia, Canada. Participants A total 5532 participants from the FOCAL trial, which women received at exit, were included...
The growing use of primary human papillomavirus (HPV) cervical cancer screening requires determining appropriate intervals to avoid overtreatment transient disease. This study examined the long-term risk precancer after HPV inform interval recommendations.
Federated learning is a decentralized framework where participating sites are engaged in tight collaboration, forcing them into symmetric sharing and the agreement terms of data samples, feature spaces, model types architectures, privacy settings, training processes. We propose PubSub-ML, Publish-Subscribe for Machine Learning, as solution loose collaboration setting each site maintains local autonomy on these decisions. In either publisher or subscriber both. The publishers publish...
To determine whether Hybrid Capture 2 High-Risk HPV DNA Test (HC2) can be used as a test of cure in women treated for cervical intraepithelial neoplasia grade or worse (CIN 2+) and allow discharge from colposcopy follow-up with return to cytology-based screening program HC2-negative women.Data were analyzed all who underwent loop electrosurgical excision procedure between August 1, 2008, June 30, 2011, had valid HC2 result after histopathology result, risk persistent recurrent CIN 2+...
Self-collection may provide an opportunity for innovation within population-based human papillomavirus (HPV) cervical cancer screening programs by providing alternative form of engagement all individuals. The primary objective was to determine willingness self-collect a vaginal sample HPV and factors that impact in individuals who participated the Human Papillomavirus For Cervical Cancer (HPV FOCAL) trial, large randomized controlled trial. A cross-sectional online survey distributed between...
Abstract Purpose To investigate predictors of cognitive decline after whole brain radiotherapy (WBRT) for metastases. Methods A secondary analysis a phase 2 clinical trial was conducted in patients who received stereotactic radiosurgery 1–10 metastases and WBRT (NCT01046123). The Montreal Cognitive Assessment (MoCA) performed at baseline every 3 months WBRT. Baseline T2-weighted fluid attenuation inversion recovery magnetic resonance imaging independently assessed by two neuroradiologists...
Measurement error or lack of proper experimental setup often results in invalid missing data gene expression studies. Small sample size and cost re-running the experiment presents a need for an efficient imputation technique. In this paper, we propose method based on Random forest using projection as pre-processing filter. Initial varying proportions variety real datasets show that process performs equally well better than K-Nearest Neighbor & Support Vector Regression methods. Using...
Abstract Background Given the heterogeneity in outcomes for de novo metastatic breast cancer (dnMBC), a staging system was recently developed that refines prognostic estimates patients presenting with distant metastases (JCO 2023;10:2546). This model using National Cancer Database and stratified into 4 subgroups, termed IVA, IVB, IVC, IVD based on 3-year overall survival (OS): IVA &gt;70%, IVB 50-70%, IVC 25-&lt; 50%, &lt; 25%; primary factors affecting higher stage grouping were...